Stoke Therapeutics, Inc. Research and Development Expense
Stoke Therapeutics, Inc. (STOK) reported Research and Development Expense of $49.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- Stoke Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $49.50M, a 91.46% increase year-over-year.
- Stoke Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $39.67M, a 21.41% increase year-over-year.
- Stoke Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $41.70M, a 78.01% increase year-over-year.
- Stoke Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $37.70M, a 69.76% increase year-over-year.
- Stoke Therapeutics, Inc. research and development expense for fiscal 2025 was $137.92M, a 54.74% increase from fiscal 2024.
- Stoke Therapeutics, Inc. research and development expense for fiscal 2024 was $89.13M, a 8.39% increase from fiscal 2023.
- Stoke Therapeutics, Inc. research and development expense for fiscal 2023 was $82.23M, a 5.65% increase from fiscal 2022.
- Stoke Therapeutics, Inc. research and development expense for fiscal 2022 was $77.84M, a 43.70% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.50M 10-Q · filed 2026-08-03 | $89.17M 10-Q · filed 2026-08-03 | $130.87M derived: sum of 3 quarters · filed 2026-08-03 | $168.56M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $39.67M 10-Q · filed 2026-05-07 | $81.37M derived: sum of 2 quarters · filed 2026-05-07 | $119.06M derived: sum of 3 quarters · filed 2026-05-07 | $144.92M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $41.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $79.39M derived: sum of 2 quarters · filed 2026-03-16 | $105.25M derived: sum of 3 quarters · filed 2026-08-03 | $137.92M 10-K · filed 2026-03-16 |
| 2025-09-30 | $37.70M 10-Q · filed 2025-11-04 | $63.55M derived: sum of 2 quarters · filed 2026-08-03 | $96.23M 10-Q · filed 2025-11-04 | $119.65M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $25.86M 10-Q · filed 2026-08-03 | $58.53M 10-Q · filed 2026-08-03 | $81.95M derived: sum of 3 quarters · filed 2026-08-03 | $104.16M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $32.68M 10-Q · filed 2026-05-07 | $56.10M derived: sum of 2 quarters · filed 2026-05-07 | $78.30M derived: sum of 3 quarters · filed 2026-05-07 | $99.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $23.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $45.63M derived: sum of 2 quarters · filed 2026-03-16 | $66.76M derived: sum of 3 quarters · filed 2026-03-16 | $89.13M 10-K · filed 2026-03-16 |
| 2024-09-30 | $22.20M 10-Q · filed 2025-11-04 | $43.34M derived: sum of 2 quarters · filed 2025-11-04 | $65.71M 10-Q · filed 2025-11-04 | $87.49M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $21.14M 10-Q · filed 2025-08-12 | $43.50M 10-Q · filed 2025-08-12 | $65.28M derived: sum of 3 quarters · filed 2025-08-12 | $85.55M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $22.37M 10-Q · filed 2025-05-13 | $44.15M derived: sum of 2 quarters · filed 2025-05-13 | $64.42M derived: sum of 3 quarters · filed 2025-05-13 | $84.97M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $21.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $42.05M derived: sum of 2 quarters · filed 2025-03-18 | $62.60M derived: sum of 3 quarters · filed 2025-03-18 | $82.23M 10-K · filed 2025-03-18 |
| 2023-09-30 | $20.27M 10-Q · filed 2024-11-05 | $40.82M derived: sum of 2 quarters · filed 2024-11-05 | $60.45M 10-Q · filed 2024-11-05 | $81.51M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $20.55M 10-Q · filed 2024-08-07 | $40.18M 10-Q · filed 2024-08-07 | $61.24M derived: sum of 3 quarters · filed 2024-08-07 | $81.35M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $19.63M 10-Q · filed 2024-05-06 | $40.69M derived: sum of 2 quarters · filed 2024-05-06 | $60.80M derived: sum of 3 quarters · filed 2024-05-06 | $79.16M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $21.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $41.17M derived: sum of 2 quarters · filed 2024-03-25 | $59.53M derived: sum of 3 quarters · filed 2024-03-25 | $77.84M 10-K · filed 2024-03-25 |
| 2022-09-30 | $20.11M 10-Q · filed 2023-11-07 | $38.47M derived: sum of 2 quarters · filed 2023-11-07 | $56.78M 10-Q · filed 2023-11-07 | $72.58M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $18.36M 10-Q · filed 2023-08-07 | $36.67M 10-Q · filed 2023-08-07 | $52.47M derived: sum of 3 quarters · filed 2023-08-07 | $66.83M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $18.31M 10-Q · filed 2023-05-04 | $34.11M derived: sum of 2 quarters · filed 2023-05-04 | $48.47M derived: sum of 3 quarters · filed 2023-05-04 | $62.56M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $30.16M derived: sum of 2 quarters · filed 2023-03-06 | $44.26M derived: sum of 3 quarters · filed 2023-03-06 | $54.17M 10-K · filed 2023-03-06 |
| 2021-09-30 | $14.36M 10-Q · filed 2022-11-14 | $28.45M derived: sum of 2 quarters · filed 2022-11-14 | $38.37M 10-Q · filed 2022-11-14 | $47.27M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $14.10M 10-Q · filed 2022-08-08 | $24.01M 10-Q · filed 2022-08-08 | $32.91M derived: sum of 3 quarters · filed 2022-08-08 | $41.02M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $9.91M 10-Q · filed 2022-05-10 | $18.82M derived: sum of 2 quarters · filed 2022-05-10 | $26.93M derived: sum of 3 quarters · filed 2022-05-10 | $34.89M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $8.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $17.01M derived: sum of 2 quarters · filed 2022-03-10 | $24.98M derived: sum of 3 quarters · filed 2022-03-10 | $32.20M 10-K · filed 2022-03-10 |
| 2020-09-30 | $8.11M 10-Q · filed 2021-11-08 | $16.08M derived: sum of 2 quarters · filed 2021-11-08 | $23.29M 10-Q · filed 2021-11-08 | $30.38M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $7.97M 10-Q · filed 2021-08-10 | $15.18M 10-Q · filed 2021-08-10 | $22.27M derived: sum of 3 quarters · filed 2021-08-10 | $28.79M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $7.21M 10-Q · filed 2021-05-10 | $14.30M derived: sum of 2 quarters · filed 2021-05-10 | $20.82M derived: sum of 3 quarters · filed 2021-05-10 | $26.84M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $7.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $13.61M derived: sum of 2 quarters · filed 2021-03-09 | $19.63M derived: sum of 3 quarters · filed 2021-03-09 | $23.76M 10-K · filed 2021-03-09 |
| 2019-09-30 | $6.52M 10-Q · filed 2020-11-12 | $12.54M derived: sum of 2 quarters · filed 2020-11-12 | $16.68M 10-Q · filed 2020-11-12 | $19.68M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $6.02M 10-Q · filed 2020-08-10 | $10.16M 10-Q · filed 2020-08-10 | $13.16M derived: sum of 3 quarters · filed 2020-08-10 | $15.39M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $4.13M 10-Q · filed 2020-05-15 | $7.14M derived: sum of 2 quarters · filed 2020-05-15 | $9.36M derived: sum of 3 quarters · filed 2020-05-15 | $11.25M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $5.23M derived: sum of 2 quarters · filed 2020-03-23 | $7.12M derived: sum of 3 quarters · filed 2020-03-23 | $8.37M 10-K · filed 2020-03-23 |
| 2018-09-30 | $2.23M 10-Q · filed 2019-11-12 | $4.12M derived: sum of 2 quarters · filed 2019-11-12 | $5.37M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $1.89M 10-Q · filed 2019-08-14 | $3.14M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |